Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.
1 report, 1 independent
Updated Aug 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Emergent BioSolutions
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA
Nothing else this week.
-
Benchmark
venture capital firm